Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 12, 1237 - 1238 (2006)
doi:10.1038/nm1106-1237
Stem cells: the good, bad and barely in control
Christian T Carson1, Stefan Aigner1 & Fred H Gage1
- The authors are at the Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, California 92037, USA. e-mail: gage@salk.edu
Abstract
The goal of replacing dying cells in Parkinson disease with stem cells is now brought a step closer to the clinic. A new protocol eases symptoms in a rat model of the disease, but also raises the concern that poorly differentiated cells have the potential to become tumorigenic (pages 1259–1268).
In principle, embryonic stem cells can be expanded and then differentiated into most cell lineages of a living organism—making them a virtually unlimited source for cell replacement therapy to treat degenerative disease or traumatic injury. In practice, however, it remains almost an art to coax human embryonic stem cells (HESCs) into generating specific cell types.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Functional engraftment of human ES cell?derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytesNature Medicine Article (01 Nov 2006)
